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Prostaglandin E2 (PGE2), one of the terminal products in the cyclooxygenase pathway, plays an important
role in various inﬂammatory responses. To determine whether selective inhibition of PGE2 may relieve
these inﬂammatory symptoms, we synthesized a selective PGE2 synthesis inhibitor, compound A [1-(6-
ﬂuoro-5,7-dimethyl-1,3-benzothiazol-2-yl)-N-[(1S,2R)-2-(hydroxymethyl)cyclohexyl]piperidine-4-
carboxamide], then investigated the effects on pyrexia, arthritis and inﬂammatory pain in guinea pigs. In
LPS-stimulated guinea pig macrophages, compound A selectively inhibited inducible PGE2 biosynthesis
in a dose-dependent manner whereas enhanced the formation of thromboxane B2 (TXB2). Compound A
suppressed yeast-evoked PGE2 production selectively and enhanced the production of TXB2 and 6-keto
PGF1a in vivo. In addition, compound A relieved yeast-induced pyrexia and also suppressed paw swelling
in an adjuvant-induced arthritis model. The effect on gastrointestinal (GI) ulcer formation was also
evaluated and compound A showed a lower GI adverse effect than indomethacin. However, compound A
failed to relieve yeast-induced thermal hyperalgesia. These results suggest that selective inhibition of
PGE2 synthesis may have anti-pyretic and anti-inﬂammatory properties without GI side effect, but lack
the analgesic efﬁcacy.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are widely
used for the treatment of rheumatoid arthritis, osteoarthritis and
inﬂammatory pain. This anti-inﬂammatory effect of NSAIDs is due
to the inhibition of cyclooxygenase (COX) activity. However, long-
term treatment of traditional NSAIDs causes severe GI disorder
because COX-derived prostanoids contribute to not only inﬂam-
matory symptoms but also tissue homeostasis such as mucosal
protection (1). There are two isoforms of COX, COX-1 and COX-2.
COX-1 is expressed constitutively and contributes to homeostasis
such as mucosal protection, whereas COX-2 is induced by: þ81 3 5740 3644.
co.jp (K. Shimada).
rmacological Society.
. Production and hosting by Elseinﬂammatory stimuli, so COX-2 is mainly contributed to inﬂam-
matory responses. To inhibit the COX-2 activity, COX-2-selective
inhibitors such as celecoxib, rofecoxib, lumiracoxib and valde-
coxib were developed. These COX-2-selective inhibitors have a
potent anti-inﬂammatory effect with lower risk of GI injury
compared with traditional NSAIDs (2, 3). However, COX-2-selective
inhibitors were revealed to increase the risk for cardiovascular
events and rofecoxib and valdecoxib were withdrawn from the
market (4, 5) Thus, there are still unmet needs for safer agents than
traditional NSAIDs and COX-2-selective inhibitors.
PGE2 is one of the prostanoids derived from COX and plays
pivotal roles in inﬂammatory symptoms. PGE2 is synthesized
through conversion of arachidonic acid by COX to unstable inter-
mediate prostaglandin H2 (PGH2) which is then catalyzed by PGE
synthase (PGES). There are three isoforms of PGES, cytosolic PGES
(cPGES), microsomal PGES (mPGES)-1 and mPGES-2. Among them,
mPGES-1 is induced by inﬂammatory stimuli like COX-2 in vitro (6,vier B.V. This is an open access article under the CC BY-NC-ND license (http://
R. Sugita et al. / Journal of Pharmacological Sciences 130 (2016) 128e135 1297) as well as in animal models of inﬂammation (8, 9). The impor-
tance of PGE2 in inﬂammatory responses has been investigated
focusing on mPGES-1. Genetic deletion of mPGES-1 reduced PGE2
synthesis and pain hypersensitivity and inﬂammation (10, 11).
Furthermore, pharmacological inhibition of mPGES-1 exhibited an
anti-inﬂammatory property without any GI side effects in animal
models (12, 13), suggesting that selective inhibition of PGE2 syn-
thesis is an alternative therapeutic concept to COX-2-selective
inhibition.
We have recently identiﬁed selective inhibitors of PGE2 syn-
thesis. In the present study, we examined the effects of compound
A, a novel selective PGE2 synthesis inhibitor, on pyrexia, inﬂam-
mation, GI injury and inﬂammatory pain by comparing it with
indomethacin and MF63, a traditional NSAID and an mPGES-1 in-
hibitor, respectively.
2. Materials & methods
2.1. Compounds
Compound A, 1-(6-ﬂuoro-5,7-dimethyl-1,3-benzothiazol-2-yl)-
N-[(1S,2R)-2-(hydroxymethyl)cyclohexyl]piperidine-4-
carboxamide, and MF63, 2-(6-chloro-1H-phenanthro-[9,10-d]imi-
dazol-2-yl)isophthalonitrile (12), were synthesized in Medicinal
Chemistry Research Laboratories, Daiichi Sankyo Co., Ltd. Indo-
methacin was purchased from SigmaeAldrich (St. Louis, MO, USA).
The chemical structure of compound A is shown in Fig. 1-A.
The compounds were suspended in 20% N, N-dimethylaceta-
mide/20% Tween80/60% saline solution (DTS solution) at the
appropriate concentrations and then orally administered at a vol-
ume of 2 ml/kg. Because of undesirable effect of DTS solution, the
administered volume was 1 ml/kg only in the case of b.i.d. treat-
ment in the adjuvant-induced arthritis experiment. DTS solution
was administered to the “vehicle” group.
2.2. Animals
Female Slc Hartley guinea pigs were purchased at the age of 4
weeks from Japan SLC (Shizuoka). The animals were housed in an
air-conditioned room with controlled temperature (23 ± 2 C) and
humidity (55 ± 20%) and a 12 h light/dark cycle (light from 8:00 to
20:00). They were fed and given water ad libitum throughout the
experimental period unless otherwise noted. They were acclimated
for about 1 week before use. All experimental procedures were
performed in accordance with the in-house guideline of the Insti-
tutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd.
2.3. Guinea pig macrophage assay
Guinea pig peritoneal macrophages were prepared as described
previously (14). Brieﬂy, liquid parafﬁn (Wako Pure Chemical In-
dustries, Osaka) was intraperitoneally injected into female Hartley
guinea pigs at a dose of 5 ml/100 g. Four days later, the guinea pigs
were euthanized by cutting the carotid artery under anesthesia,
and the peritoneal macrophages were collected. Macrophages were
seeded in a 96-well plate at a density of 200,000 cells/well, and pre-
treated with 100 mM aspirin (SigmaeAldrich) at 37 C for 2 h in
RPMI 1640 (Life Technologies, Waltham, MA, USA) supplemented
with 10% FBS and PenicillineStreptomycin (Life Technologies). The
cells were washed twice to remove non-adherent cells, then pre-
incubated at 37 C for 1 h with a compound or vehicle (DMSO
1%) in 200 ml of RPMI medium. The cells were treated with 10 mg/ml
lipopolysaccharide (LPS, SigmaeAldrich) at 37 C and 5% CO2 for
24 h (for time course study, incubation time was 2, 4, 7, 24 and
48 h), then PGE2 and TXB2 in the mediumwere measured by EIA kit(Assay Designs, Ann Arbor, MI, USA). Each experiment was per-
formed in duplicate.2.4. Western blot analysis
LPS-stimulated macrophages were harvested at appropriate
time points, then sonicated for 10 s twice in ice-cold phosphate
buffered saline (PBS) containing 5 mM EDTA and protease inhibitor
cocktail (Roche). Equal amounts of each lysate (5 mg) were sepa-
rated by SDS-PAGE, transferred to a polyvinylidene diﬂuoride
membrane (Merck Millipore, Billerica, MA, USA), and blocked for
30 min in Tris-buffered saline containing 5% skimmilk. Membranes
were incubated with antibodies to mPGES-1 (Cayman Chemical,
Ann Arbor, MI, USA) or COX-2 (Immuno-Biological Laboratories,
Gunma) for 1 h, with peroxidase-conjugated secondary antibody
for 1 h, and were developed with ECL-plus reagent (Life
Technologies).2.5. Pharmacokinetic study
Compound A was administered orally at 10 mg/kg to female
Hartley guinea pigs (n ¼ 3). Blood was drawn at 0.5, 1, 2, 4, 6, 8 and
24 h after administration. Compound concentrations in plasma
were measured by liquid chromatography with the tandem mass
spectrometry (LC-MS/MS) method. Brieﬂy, compound A was
extracted with acetonitrile. The LC-MS/MS system consisted of an
Agilent series 1100 (Agilent Technologies) and a tandem mass
spectrometer (API 4000; Applied Biosystems, Grand Island, NY,
USA). Chromatographic separation was performed in a Shim-pack
XR-ODS column (2 mm i.d.  30 mm; Shimadzu Corp., Kyoto).
Themobile phase consisted of solvent A, 5 mM ammonium acetate/
acetonitrile (5:95, v/v), and solvent B, 5 mM ammonium acetate/
acetonitrile (95:5, v/v) with an A/B gradient of 99:1 (0 min), 50:50
(0 mine0.1 min), 50:50 (0.01 mine0.5 min), 0:100 (0.5 mine1min)
and 0:100 (1 mine1.75 min) at a ﬂow rate of 0.75 ml/min. The
analysis was carried out in the multiple reaction monitoring mode
by measuring precursor-product ion pairs of m/z 420.9/ 209 for
compound A andm/z 283/ 265 for niﬂumic acid (SigmaeAldrich)
used as an internal standard. The calibration curves for compound
A were constructed at 5 nMe500 nM for plasma. The precision of
analysis at LOQ did not exceed 15% and accuracy was in the range of
85%e115%.2.6. Prostanoid content in inﬂamed tissue
After overnight fasting, 20% suspension of brewer's yeast (Sig-
maeAldrich) was injected into the right hind paws of the guinea
pigs (0.1 ml of saline) to induce inﬂammation. Four hours after the
injection, the animals were euthanized and the inﬂamed right hind
paws were immediately removed and weighed. The paws were
snap frozenwith liquid nitrogen and stored at80 C until use. The
paws were then crushed with a Cryo-press® (Microtec Co., Ltd.,
Chiba) in the presence of liquid nitrogen and homogenized with a
Polytron® homogenizer at 4 C for 60 s in four times the volume of a
paw of PBS with 10 mM EDTA and 100 mM indomethacin. The ho-
mogenatewas centrifuged at 1560g for 15min at 4 C, and 1ml of
the supernatant fraction was further centrifuged at 9500 g for
5 min at 4 C, and the supernatant was then stored at 20 C until
the prostanoid assay. Compound A, MF63 and indomethacin were
orally administered 2, 4 and 5 h before euthanization, respectively
(n ¼ 5). PGE2, 6-keto PGF1a and TXB2 were measured with
respective EIA kit (Cayman Chemical) according to the manufac-
turer's instructions.
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Fig. 1. Inhibitory effect of compound A on LPS-induced prostaglandin synthesis in guinea pig macrophages. (A) Chemical structure of compound A. (B) Time-course analysis of COX-
2 (upper) and mPGES-1 (lower) expression after LPS stimulation in guinea pig macrophages. (C) Time-course analysis of PGE2 synthesis with or without LPS stimulation in guinea
pig macrophages. (D and E) Dose dependent effect of compound A (D) and MF63 (E) on the production of PGE2 and TXB2 in guinea pig macrophages. Data are expressed as % amount
of LPS-stimulated control. Results are shown as the mean ± S.D. (in duplicate).
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Experiments were performed according to the method as
described previously with some modiﬁcations (15). Pyrexia was
induced with 2 ml of 20% suspension of brewer's yeast was injected
subcutaneously into female guinea pigs. After about 18 h, rectal
temperature was taken using a digital rectal thermometer (Phys-
itemp Instruments, Clifton, NJ, USA) and animals with a tempera-
ture over 39.5 Cwere selected for pyretic assays. Test compound or
vehicle (DTS solution) was orally administered to the selected an-
imals and then the body temperature was measured at 1, 2, 3, 4 and5 h after the dosing (n¼ 5e7). Non-injected animals were used as a
control.
2.8. Adjuvant-induced arthritis model
An adjuvant was prepared by suspending heat-killed dried
Mycobacterium butyricum (BD biosciences, San Jose, CA, USA) in
dry-sterilized liquid parafﬁn (2 mg/ml) and then sonicated with a
Soniﬁer Cell Disruptor 200 (Branson Ultrasonic, Danbury, CT, USA).
The adjuvant was injected 0.05 ml (100 mg/animal) intradermally
into the heels of the right hind footpads of the guinea pigs on Day 0.
0
1
2
3
4
5
6
7
8
9
0 5 10 15 20
Pl
as
m
a 
C
on
c.
 (μ
M
)
Hours after administration
Fig. 2. Time-course of plasma concentration of compound A after oral administration
(10 mg/kg) in guinea pigs. Results are shown as the mean ± S.D. (n ¼ 3/time point).
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q.d., respectively (n ¼ 6). The volume of the adjuvant-injected foot
was measured every day until Day 7 using a plethysmometer (Ugo
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Fig. 3. Inhibitory effect of compound A (A), MF63 (B) and indomethacin (C) on yeast-induc
suspension of brewer's yeast. Paw tissues were harvested 4 h after yeast injection. Compo
respectively. Results are shown as the mean ± S.E.M. (n ¼ 5) *, p < 0.05; **, p < 0.01; ***, p2.9. Gastric mucosal lesion experiments
In order to prevent guinea pigs from coprophagia, Elizabethan
collars were ﬁtted onto them and the animals were fasted over-
night. The guinea pigs were euthanized 4 h after oral administra-
tion of the test compounds (n ¼ 5e10). The stomach was removed,
washed with 10 ml of PBS, ligated at the esophagus with forceps
and 10 ml of 10% formaldehyde solution was poured into the
stomach from the duodenum. The stomach was opened along the
greater curvature after immersing it in 10% formaldehyde solution
for 10 min. The mucosa was then examined for the presence of
hemorrhage lesions under a stereomicroscope. All dark brown
hemorrhage lesions longer than 0.5 mm in length were measured
and the total length was determined for the individual animal.
Animals which had hemorrhage lesions with a total length longer
than 2.0 mmwere considered to be lesion positive. The incidence of
positive animals was determined in each group.
2.10. Yeast-induced thermal hyperalgesia
After overnight fasting, 0.1ml of 20% brewer's yeast was injected
into the left hind paws of the guinea pigs. Paw withdrawal latency
(PWL) was measured 2 and 3 h after yeast injection using a Plantar
test instrument (Hargreaves Apparatus, Ugo Basile). Animals of1α
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Fig. 4. Anti-pyretic effect of compound A (A) and MF63 (B) on the yeast-induced py-
rexia in guinea pigs. Pyrexia was induced by the subcutaneous injection of 2 ml of 20%
suspension of brewer's yeast. After 18 h, each compound or vehicle (DTS solution) was
orally administered to animals which cause fever. Rectal temperature was measured
every 1 h until 5 h after administration. Results are shown as the mean ± S.E.M.
(n ¼ 5e7/group) *, p < 0.05; **, p < 0.01; ***, p < 0.001 for compound-versus vehicle-
treated animals.
R. Sugita et al. / Journal of Pharmacological Sciences 130 (2016) 128e135132which PWL at 3 hwas less than 7 s were selected. Test compound or
vehicle was orally administered and PWL was measured 1, 2, 3 and
4 h after administration (n ¼ 5e6).
2.11. Statistical analysis
In macrophage assays and pharmacokinetic study, data are
expressed as the mean ± S.D. and other data are expressed as the
mean ± S.E.M. The statistical analysis was performed by Dun-
nett's test for multiple comparisons. In the inﬂamed tissue assay,
the percent inhibition of prostanoid content by a compound was
calculated by the following equation: 1{(prostanoid content of a
compound-treated animal)(a prostanoid content of a normal
group)}/{(prostanoid content of a vehicle-treated group)-
(prostanoid content of a normal group)}  100. ID50 values were
calculated based on linear regression lines obtained from the
percent inhibitions and the logarithmic values of the doses by the
least squares method. In the pyresis assay, the percent inhibition
by a compound was calculated by the following equation: 1{(a
temperature of a compound-treated animal)(a temperature of a
normal group)}/{(a temperature of a vehicle-treated group)(a
temperature of a normal group)}  100. ID50 values were calcu-
lated based on linear regression lines obtained from the percent
inhibitions (the maximal activity of each dose) and the logarith-
mic values of the doses by the least squares method. In the gastric
mucosal lesion experiments, UD50 values (doses producing 50%
incidence) were calculated by the Probit method based on the
incidence of positive animals as a function of the compound
doses.
3. Results
3.1. Compound A selectively suppressed PGE2 production in guinea
pig macrophage assay
Because compound A had no inhibitory activity of PGE2 syn-
thesis in male rats and mice macrophage assay (data not shown),
guinea pigs were used for the evaluation of compound A
throughout this paper. In guinea pig macrophage assay, LPS
induced COX-2 and mPGES-1 expression with peak at 7 and 24 h,
respectively (Fig. 1-B). In addition, LPS also induced PGE2 synthesis
which peaked at 24 h (Fig. 1-C), thus, incubation time was decided
to be 24 h. TXB2 synthesis was also induced by LPS stimulation
from 0 ng/ml to 13.2 ng/ml. Compound A suppressed PGE2 pro-
duction in a dose-dependent manner with an IC50 value of
19.6 nM, whereas this compound enhanced TXB2 synthesis (Fig. 1-
D). MF63 also suppressed PGE2 selectively with an IC50 value of
63 nM (Fig. 1-E).
3.2. Compound A showed a good oral absorption using DTS solution
in guinea pigs
The pharmacokinetic proﬁle of compound A in guinea pigs was
examined. Because compound A suspended with 0.5% methyl cel-
lulose had poor oral absorption (data not shown), DTS solution was
used as a solvent for this compound. After compound A was orally
administered at a dose of 10 mg/kg, it was rapidly absorbed and
plasma concentration reached up to 6.7 mM (Cmax) at 0.5 h, and then
gradually decreased to 0.29 mM at 8 h with t1/2 of 2.7 h (Fig. 2).
3.3. Compound A selectively suppressed PGE2 production in the
inﬂamed tissue
Inhibitory effects of compound A on PGE2, TXB2 and the 6-
keto PGF1a content were assessed in the brewer's yeast-injected tissue of guinea pigs. While TXB2 synthesis was
increased only slightly, PGE2 and 6-keto-PGF1a levels were
drastically increased 4 h after the injection of brewer's yeast.
Compound A selectively suppressed PGE2 production with an
ID50 value of less than 3 mg/kg, whereas 6-keto PGF1a and TXB2
levels were increased (Fig. 3-A). MF63 also suppressed PGE2
production selectively with an ID50 value of less than 10 mg/kg
and tended to enhance 6-keto PGF1a synthesis (Fig. 3-B). In
contrast, indomethacin suppressed all prostanoids and ID50 value
for PGE2 was 2.4 mg/kg (Fig. 3-C).
3.4. Compound A improved yeast-induced pyrexia in guinea pigs
The anti-pyretic effect of the compound was assessed in a
guinea pig model of yeast-induced pyrexia. A subcutaneous injec-
tion of brewer's yeast caused a time-dependent increase of rectal
temperature reaching 39.8 C at 18 h after injection. Compound A
dose-dependently showed anti-pyretic properties with an ID50
value of 6.9 mg/kg (Fig. 4-A). MF63 also improved the fever with an
ID50 value of 9.2 mg/kg (Fig. 4-B). Indomethacin also showed a
strong anti-pyretic effect at a dose of 30 mg/kg.
-30
-20
-10
0
10
20
30
40
50
60
0 1 2 3 4 5 6 7
B
od
y 
w
ei
gh
t (
g)
Days after adjuvant injection
Vehicle
Compound A 10 mg/kg
Compound A 30 mg/kg
Compound A 100 mg/kg
0.0
0.5
1.0
1.5
2.0
2.5
0 1 2 3 4 5 6 7
Pa
w
 v
ol
um
e 
(m
l)
Days after adjuvant injection
Vehicle
Compound A 10 mg/kg
Compound A 30 mg/kg
Compound A 100 mg/kg
*
0.0
0.5
1.0
1.5
2.0
2.5
0 1 2 3 4 5 6 7
Pa
w
 v
ol
um
e
(m
l)
Days after adjuvant injection
Vehicle
Indomethacin 10 mg/kg
Indomethacin 30 mg/kg
Indomethacin 100 mg/kg
A
B
C
D
-30
-20
-10
0
10
20
30
40
50
60
0 1 2 3 4 5 6 7
B
od
y 
w
ei
gh
t (
g)
Days after adjuvant injection
Vehicle
Indomethacin 10 mg/kg
Indomethacin 30 mg/kg
Indomethacin 100 mg/kg
** **
******* ****
* * *
*
**
**
N.S.
Fig. 5. Effect of compound A (A and C) and indomethacin (B and D) on the development of adjuvant arthritis (A and B) and weight gain (C and D) in guinea pigs. Animals received a
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adjuvant-induced arthritis model
The anti-inﬂammatory effect of compound Awas investigated in
a guinea pig chronic inﬂammation model. As shown in Fig. 5A, the
paws of the adjuvant-treated animals drastically swelled starting 6
days after the injection. The paw swelling was suppressed only
when compound Awas administrated b.i.d. at 100 mg/kg (Fig. 5-A).
Indomethacin also inhibited paw swelling at 100 mg/kg q.d (Fig. 5-
B). While 100 mg/kg of indomethacin prevented weight gain,
compound A showed no effect on body weight (Fig. 5-C and D).3.6. Compound A had a lower risk of GI disorder
Gastric mucosal lesion formation was evaluated in guinea pigs
with a single dose of compound A or indomethacin. Oral admin-
istration of compound A caused a weak mucosal lesions and 20% of
lesion positive animals at 100 mg/kg. On the other hand, indo-
methacin caused dose-dependent lesion formation with a UD50 of
15 mg/kg (Table 1).3.7. Compound A showed weaker analgesic effect than traditional
NSAIDs in yeast-induced thermal hyperalgesia model
The anti-hyperalgesic effect of compound A in guinea pigs was
assessed in a yeast-induced thermal hyperalgesiamodel. Compared
with normal mice, PWL of brewer's yeast-injected mice was
shortened from 19.5 s (normal) to 4.8 s. Indomethacin at 30 mg/kg
signiﬁcantly prolonged PWL at 3 and 4 h after drug administration.
In contrast, compound A did not show any effect on PWL even at
100 mg/kg (Fig. 6).
4. Discussion
Selective inhibition of PGE2 synthesis is thought to be an alter-
native therapeutic target for anti-inﬂammatory agents. In the pre-
sent study, we investigated the pharmacological proﬁle of a
selective PGE2 synthesis inhibitor by comparing it with a COX-
nonselective inhibitor. In the guinea pig macrophage assay, LPS
stimulation induced COX-2 expression followed by mPGES-1
expression which was correlated with PGE2 synthesis. Compound
A selectively suppressed the synthesis of PGE2, whereas the
Table 1
Effect of compound A and indomethacin on gastric mucosal lesion formation in
guinea pigs.
Dose
(mg/kg)
Total length of
hemorrhage lesions
(mm, mean±S.E.M)
Incidence of lesion
positive animals
(%)
UD50
(mg/kg)
Compound A 0 0.6±0.4 0 >100
30 1.0±0.6 0
100 4.0±2.3 20
Indomethacin 3 3.0±1.4 20 15
10 1.8±0.9 20
30 15.2±5.6 80
100 43.6±9.5 90
R. Sugita et al. / Journal of Pharmacological Sciences 130 (2016) 128e135134synthesis of TXB2 was enhanced. On the other hand, MF63, an
mPGES-1 inhibitor, suppressed PGE2 synthesis selectively, but did
not change TXB2 synthesis. Because MF63 is reported to suppress
PGE2 and enhance PGF2a production in A549 cells (12), this com-
pound may enhance other prostanoids than TXB2 in the present
study. Genetic deletion of mPGES-1 is also reported to show the
enhancement of other prostanoids (16,17). Since all prostanoids are
catalytically synthesized from the same substrate, PGH2, it is sug-
gested that the selective inhibition of PGE2 synthesis leads to the
accumulation of PGH2 which is rapidly converted to other prosta-
noids. To the best of our knowledge, there is no other mechanism
for the redirection of prostanoids. Thus, compound A appears to be
a PGES (probably mPGES-1) inhibitor.
Since compound A showed a good oral availability in DTS so-
lution in the pharmacokinetic study (Fig. 2), we examined the
inhibitory potency of this compound in guinea pig models of
inﬂammation. In a yeast-induced inﬂammation test, while indo-
methacin suppressed all prostanoids, compound A and MF63
suppressed PGE2 synthesis selectively in inﬂamed tissue. In this
study, 6-keto-PGF1a production was substantially induced and
further enhanced by compound A or MF63 treatment. Although
TXB2 synthesis was also enhanced signiﬁcantly by compound A, the
enhanced amount was smaller than that of 6-keto-PGF1a, sug-
gesting the redirection proﬁle may depend on production capa-
bility in each cell type or tissue.
Anti-pyretic effect is a well-known feature of NSAIDs and py-
rexia is mediated primarily by PGE2 produced by COX-2 and0
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Fig. 6. Analgesic effect of compound A and indomethacin on yeast-induced thermal
hyperalgesia in guinea pigs. Left hind paw was injected 0.1 ml of 20% suspension of
brewer's yeast. After hyperalgesia-induced animals were selected, compound A,
indomethacin, or vehicle (DTS solution) was orally administered. Paw withdrawal la-
tency was measured 1, 2, 3 and 4 h after administration. Results are shown as the
mean ± S.E.M. (n ¼ 5e6/group) *, p < 0.05; **, p < 0.01 for compound-versus vehicle-
treated animals.mPGES-1 (18e20). Thus, anti-pyretic effect of compound A was
assessed. As expected, compound A dose-dependently improved
pyrexia induced by yeast injection comparable to indomethacin
and MF63, indicating this compound may be useful for the treat-
ment of fever. However, the effect of compound Awas weakened at
5 h after administration. Because plasma concentration of com-
pound A reached Cmax at 0.5 h and relatively rapidly decreased, it
may not be enough plasma concentration to keep the anti-pyretic
effect at 5 h. Thus, pharmacokinetic improvement may prolong
the duration of effectiveness.
Traditional NSAIDs and COX-2-selective inhibitors are used to
treat arthritis such as rheumatoid arthritis and osteoarthritis, and
PGE2 contributes to these pathologies (21e23). Thus, we examined
whether our compound has a potent anti-inﬂammatory effect in an
adjuvant-induced arthritis model. Compound A was administered
b.i.d. from the day when adjuvant was injected, and suppressed the
establishment of arthritis at 100 mg/kg without inhibiting weight
gain. On the other hand, indomethacin showed a strong anti-
inﬂammatory effect at 100 mg/kg (q.d.). However, this dose also
inhibited weight gain, suggesting adverse effects on biological ac-
tivities including GI disorder. Because such adverse effects may
affect the inﬂammatory response, the inhibitory effect of indo-
methacin on paw volume may not reﬂect a beneﬁcial effect. Indo-
methacin is well used as a positive control in a rat adjuvant-
induced arthritis model at the dose of about 3 mg/kg, but it
showed no effect even at 10 mg/kg in the present guinea pig model.
Although the precise reason remains unknown, the species differ-
ence between rats and guinea pigs may attribute to the difference
of efﬁcacy of indomethacin. Thus, the comparison of anti-
inﬂammatory potency with traditional NSAIDs or COX-2-selective
inhibitors should be further assessed using other models.
GI disorder is a major side effect of traditional NSAIDs, so we
assessed whether our compound has a risk of GI ulcer formation.
Indomethacin strongly induced gastric mucosal lesions and the
safety margin was 6.25, which is calculated from the ID50 of PGE2
synthesis in vivo (2.4 mg/kg, Fig. 3-C) and UD50 of GI lesion
(15 mg/kg, Table 1). In contrast, compound A induced only 20% of
lesion positive animals at 100 mg/kg and the safety margin was
more than 30, suggesting that our compound has a lower risk of GI
disorder than traditional NSAIDs. Other reports also suggest the GI
tolerability of selective inhibition of PGE2 synthesis or signal. For
instance, MF63 did not produce mucosal erosions and blood feces
in human mPGES-1 knock-in mice and squirrel monkeys, respec-
tively (12). In addition, selective E prostanoid receptor 4 (EP4) an-
tagonists also show anti-inﬂammatory effects and are well
tolerated by the GI tract (24, 25). Not only PGE2, but also PGI2
contributes to mucosal protection (26), and in the present study,
while indomethacin suppressed all prostanoids, compound A did
not suppress 6-keto-PGF1a synthesis. Thus, unlike traditional
NSAIDs, PGI2 could compensate the loss of PGE2 in gastric mucosa
of compound A-treated animals, which may be the reason for the
lower adverse effect on the GI tract.
Finally, we evaluated the analgesic effect of our compound.
Yeast injection induced thermal hyperalgesia in guinea pigs and
indomethacin improved it. However, compound A showed little
effect in this model even at the dose of 100 mg/kg, which sup-
pressed PGE2 synthesis almost to the normal level in the PGE2
synthesis study (Fig. 3-A). It is still under debate whether selective
inhibition of PGE2 synthesis achieves a potent analgesic property
comparable to traditional NSAIDs or COX-2-selective inhibitors. The
analgesic property of MF63 is reported in a model of LPS-induced
thermal hyperalgesia in guinea pigs (12), whereas genetic dele-
tion of mPGES-1 failed to relieve COX-2-dependent zymosan-
evoked hyperalgesia (27). Among all prostanoids other than PGE2,
PGI2 (prostacyclin) is also known as amediator of inﬂammation and
R. Sugita et al. / Journal of Pharmacological Sciences 130 (2016) 128e135 135inﬂammatory pain (28). In addition, a prostacyclin receptor
antagonist is reported to reduce pain and inﬂammation in mice
chronic arthritis models (29). Because compound A enhanced the
production of 6-keto-PGF1a, PGI2 is likely to contribute to pain
perception. Our results suggest the selective inhibition of PGE2
synthesis may be insufﬁcient to exert an analgesic effect, but
further investigation will be needed to clarify this question.
In summary, we evaluated the effect of our selective PGE2 syn-
thesis inhibitor on pyrexia, arthritis, GI tract, and inﬂammatory
pain in guinea pigs. Our compound selectively reduced the pro-
duction of PGE2, whereas other prostanoids such as TXB2 and 6-
keto-PGF1a promoted its increase. In in vivo studies, this com-
pound relieves pyrexia and arthritis, and shows a lower amount of
GI adverse effects than traditional NSAIDs. However, it fails to
reduce inﬂammatory thermal hyperalgesia. These results suggest
that our compound may be useful for pain-free inﬂammatory dis-
eases as an alternative to traditional NSAIDs and also for evaluation
of the roles of PGE2 synthesis on physiological and pathological
conditions.
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